SciClone climbs on earnings

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) jumped $1.67 (21%) to $9.66 on Tuesday after reporting earnings postmarket Monday and raising its FY15 EPS guidance. The company reported non-GAAP diluted EPS of $0.26 in 3Q15, up from $0.17 in 3Q14. For the year, SciClone raised its guidance to $0.93-$0.97 from $0.73-$0.77, citing strong demand for Zadaxin thymalfasin and the implementation of operating cost control measures.

Zadaxin posted 3Q15 sales of $39.2 million, up 22% from $32.1 million in 3Q14. The synthetic thymosin alpha-1 is approved in more than 30 countries for HBV, HCV and certain cancers, and as a vaccine adjuvant. ...